NCT Number: NCT02056652
Prevention of Preterm Birth With a Pessary in Singleton Gestations
Preterm birth (PTB) is associated with over one million infant deaths annually worldwide. The incidence of PTB in the United States is 11.5% with more than 500,000 deliveries occurring at less than 37 weeks gestation annually. The rate of PTB in the United States increased to 12.8% in 2006, and remains high compared to almost all other developed countries, despite the introduction of many public health and medical interventions designed to delay PTB. Weekly treatment with 17-alpha hydroxyprogesterone caproate beginning at 16-20 weeks gestation has been shown to significantly reduce the risk of PTB and is currently recommended for women who experienced spontaneous PTB in a prior pregnancy. However, a strategy for the prevention of spontaneous PTBs in which therapeutic intervention is restricted to women with a previous PTB is likely to have a small effect on the overall rate of prematurity since only about 10% of spontaneous PTBs arise in women with such a history. A major reduction in rates of mortality and morbidity in premature babies will only be achieved with increased precision in the identification of women at risk of spontaneous PTB and through the development of an effective prevention for this complication. Transvaginal ultrasound measurement of cervical length is a reliable screening test for prediction of PTB. Although treatment with vaginal progesterone is effective in decreasing PTB in women with a short cervix, over 30% of women still experience premature delivery and many women find daily administration of progesterone to be challenging. Preliminary studies have suggested that use of an intravaginal pessary may be effective in preventing PTB. If effective this approach would be particularly appealing because of the wide availability of pessaries, ease of use, and low cost. Unfortunately, existing studies are inadequate to confirm effectiveness; a well designed, properly powered, prospective randomized trial is warranted prior to widespread implementation in clinical practice. We propose such a trial to study the effectiveness of the pessary in decreasing the incidence of PTB in an inner city Philadelphia population.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–50 year
Sex eligibility
Female
Study type
Interventional
Phase
Not applicable
Primary location
Geisinger Medical Center, Danville, Pennsylvania, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- 18-50 years of age
- Singleton pregnancy (limits the participants to female gender)
- Short cervical length (less than or equal to 25 mm) on second trimester ultrasound at 18-23 6/7 weeks gestation
Exclusion criteria
- Multiple gestation
- Prior spontaneous preterm birth 16-36 6/7 weeks
- Ruptured membranes
- Lethal fetal structural anomaly
- Fetal chromosomal abnormality
- Cerclage in place (or planned placement)
- Vaginal bleeding
- Suspicion of chorioamnionitis
- Ballooning of membranes outside the cervix into the vagina or CL = 0 mm on transvaginal ultrasound
- Painful regular uterine contractions
- Placenta previa
Treatment and study plan
Primary outcomes
-
Number of Subjects Experiencing Preterm Birth
Time frame: Before 37 weeks gestation (20 0/7 - 36 6/7 weeks)
Birth before 37 weeks gestation was captured.
Secondary outcomes
-
Average Birth Weight of Babies Born on Trial
Time frame: Time of delivery
The birth weights of babies born in the pessary group was compared to those born in the no pessary group
-
Number of Participants That Experienced Spontaneous Preterm Births on Trial
Time frame: Before 37 weeks gestation
The number of spontaneous births that occurred in participants on trial before 37 weeks was captured.
-
Number of Participants Experiencing Spontaneous Rupture of Membranes
Time frame: Less than 34 weeks gestation
Rupture of membranes before 34 weeks gestation was captured in each group.
-
Number of Subjects Experiencing Neonatal Death
Time frame: Between birth and 28 days of age
Number of participants who experienced neonatal deaths from birth to day 28 was captured for each group.
-
Number of Subjects Experiencing Chorioamnionitis
Time frame: Time of delivery
The AE of Chorioamnionitis was captured for each group.
Sponsors and collaborators
Lead sponsor
University of Pennsylvania
Other
Registry information
Acronym: PoPPS
Important dates
- Study start
- 2014
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Feb 6, 2014
- Registry last updated
- May 29, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Canadian Study on the Association of Pessary With Progesterone
NCT03227705
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Kingston, Ontario, Canada
View Trial DetailsCerclage With Progesterone Versus Progesterone Only in Singleton Pregnancies
NCT06463652
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Ho Chi Minh City, Vietnam
View Trial DetailsHippo-YAP Pathway and Related miRNAs in Preterm Birth
NCT07695467
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Sivas, Kayseri Ave, Turkey (Türkiye)
View Trial DetailsBEP Supplementation Research in Bangladesh (JiVitA-BEP-IR)
NCT05576207
Anemia of Pregnancy, Birth Weight
Rangpur City, Bangladesh
View Trial Details